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Abstract
Influenza is a major cause of morbidity and mortality in immunosuppressed persons, and vaccination often confers
insufficient protection. IL-28B, a member of the interferon (IFN)-l family, has variable expression due to single nucleotide
polymorphisms (SNPs). While type-I IFNs are well known to modulate adaptive immunity, the impact of IL-28B on B- and T-
cell vaccine responses is unclear. Here we demonstrate that the presence of the IL-28B TG/GG genotype (rs8099917, minor-
allele) was associated with increased seroconversion following influenza vaccination (OR 1.99 p = 0.038). Also, influenza A
(H1N1)-stimulated T- and B-cells from minor-allele carriers showed increased IL-4 production (4-fold) and HLA-DR
expression, respectively. In vitro, recombinant IL-28B increased Th1-cytokines (e.g. IFN-c), and suppressed Th2-cytokines
(e.g. IL-4, IL-5, and IL-13), H1N1-stimulated B-cell proliferation (reduced 70%), and IgG-production (reduced.70%). Since IL-
28B inhibited B-cell responses, we designed antagonistic peptides to block the IL-28 receptor a-subunit (IL28RA). In vitro,
these peptides significantly suppressed binding of IFN-ls to IL28RA, increased H1N1-stimulated B-cell activation and IgG-
production in samples from healthy volunteers (2-fold) and from transplant patients previously unresponsive to vaccination
(1.4-fold). Together, these findings identify IL-28B as a key regulator of the Th1/Th2 balance during influenza vaccination.
Blockade of IL28RA offers a novel strategy to augment vaccine responses.
Citation: Egli A, Santer DM, O’Shea D, Barakat K, Syedbasha M, et al. (2014) IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza. PLoS
Pathog 10(12): e1004556. doi:10.1371/journal.ppat.1004556
Editor: Michael Gale Jr., University of Washington, United States of America
Received April 17, 2014; Accepted November 5, 2014; Published December 11, 2014
Copyright:  2014 Egli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work is partly funded by a grant from the Li Ka Shing Institute of Virology. AE research is supported by a salary research grant by the Swiss National
Science Foundation (PBBSP3-130963) and a Lichtenstein Foundation grant. AL is supported by the Banting Postdoctoral Fellowship Program, administered by the
Government of Canada and by Alberta Innovates Health Solutions Postdoctoral Fellowship, DMS is supported by Canadian Institutes of Health Research and
Alberta Innovates Health Solutions Postdoctoral Fellowships, BST is supported by the National CIHR Research Training Program in Hepatitis C (NCRTP-HepC), LFL
is supported by a research Fellowship grant from the Canadian Society of Transplantation, MH is supported by the Canada Excellence Research Chair (CERC) in
Virology award. DLJT is supported by a grant of the Canadian Institute of Health Research. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors of this manuscript have conflicts of interest to disclose as D.K. and A.H. have received research support from Hoffmann-
LaRoche. This does not alter our adherence to all PLOS policies on sharing data and materials.
* Email: a.egli@usb.ch
" These authors are joint senior authors on this work.
Introduction
Generation of a protective and durable immune response is the
major challenge of effective vaccinations against influenza. On a
global scale, infection with influenza viruses is associated with
increased morbidity and mortality in elderly persons, pregnant
women and immunosuppressed individuals [1]. The primary
means to limit this disease is through annual influenza vaccination
as recommended [2]. However, annual influenza vaccines are
poorly effective in the elderly, and immunocompromised popula-
tions [3–5]. For example, after organ transplantation, post-vaccine
seroconversion rates only approach 30 to 50% [4,6,7]. Although
this may be a function of diminished adaptive immune responses,
there are increasing data that interferons (IFN) may modulate
vaccine responses [8–12]. Understanding the factors involved in a
successful vaccine response and seroconversion will allow optimi-
zation of vaccine strategies [13].
The IFN-l family (Interleukin-28A, -28B, -29, and IFN-l4) is a
recently described class of IFNs with antiviral properties similar to
IFN-a and -b [14–17]. IFN-l is known to induce phosphorylation
of STAT-1 and -2 via binding to its receptor, which is a
heterodimer consisting of the IL-28 receptor alpha subunit
(IL28RA) and IL-10 receptor beta subunit (IL10RB) [16]. In
addition to their anti-viral effects, one of the IFN-l family
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members (IL-29) has been shown to increase Th1 and suppress
Th2 cytokine producing T-cells [18–21]. Furthermore, IFN-ls
induced the development of T-regulatory cells in vitro [22,23].
These findings indicate the substantial role of IFN-ls in immune
responses, however, this has not been explored in the context of
vaccine responses or influenza infection.
Single nucleotide polymorphisms (SNPs) in IL-28B are divided
according to their frequencies in a population. At rs8099917, TT
is the major-allele and TG or GG are minor-allele genotypes; at
rs12979860, CC is the major-allele and CT or TT are minor-allele
genotypes [24–27]. We selected these two SNPs as they are
commonly described in the literature to affect IL-28B functions.
Since IFN expression is involved in multiple aspects of the
immune response, we hypothesized that the effectiveness of
vaccination may be modulated by variation in IL-28B expression
as a consequence of SNPs. We further explored the possibility that
altered expression of IL-28B might be associated with changes in
B- and T-cell responses. In this study, we chose to use clinical
samples obtained from organ transplant patients. These patients
receive lifelong immunosuppression and have impaired adaptive
immune responses to vaccination. Therefore, any impairment of
the innate immune response which alters stimulation of adaptive
immunity, is likely to take on greater importance. This population
also stands to have the greatest gain from strategies to augment
vaccine responses.
Here we show that transplant patients that carry minor-alleles in
the IL-28B (rs8099917, TG or GG) gene have significantly higher
rates of seroconversion following influenza vaccination. PBMCs
from transplant patients with the minor-allele expressed less Th1
cytokines, had more IL-4 producing H1N1-specific T-cells, and
higher HLA-DR activation marker expression on naive B-cells
than those from major-allele carriers. Consistent with these
findings, in vitro addition of IL-28B to PBMCs increased Th1
cytokine expression, decreased Th2 cytokines, and decreased
H1N1 stimulated B-cell proliferation and IgG production. We also
show healthy volunteer PBMCs from minor-allele carriers
stimulated with H1N1 expressed less IL-28B. Antagonistic
peptides designed to block the interaction between IL-28B and
its receptor, reversed these effects and could potentially be used as
a novel class of vaccine adjuvants.
Results
SNPs in IL-28B affect vaccine responses in organ
transplant recipients
Transplant recipients carrying the minor-allele of IL-28B
have increased seroconversion following influenza
vaccination. We obtained blood samples from a cohort of
transplant recipients (n = 196) on maintenance immunosuppres-
sion that were originally recruited as part of a randomized
controlled trial of intradermal versus intramuscular influenza
vaccination [28]. Patient demographics are shown in S1 Table.
Patients were genotyped for IL-28B SNPs (rs8099917 and
rs12979860) and the genotypic distribution is shown in S2 Table
and was in equilibrium with general population distribution
[24–27].
We found that minor-allele carriers for the SNP rs8099917 (TG
or GG) were significantly more likely to undergo seroconversion to
at least one antigen of the influenza vaccine (OR 1.99, 95% CI
1.07–3.69; Fig. 1A). This effect was even higher in a homozygous
minor-allele genotype, where the GG-genotype resulted in a
seroconversion rate of 85.7% (Fig. 1B). S1A–C Figure shows that
the HAI geometric mean titers for pH1N1, H3N2 and Influenza B
before and after vaccination are higher in TG or GG (minor allele
carriers) versus TT (major allele carriers). For pH1N1, the post-
vaccine geometric mean titers of patients with the TT genotype
were 66.2, for TG 93.8, and for GG 113.2. The median fold
changes from pre- to post-vaccine were 2-fold in TT genotypes, 3-
fold in TG and 4-fold in GG. For H3N2, the post-vaccine
geometric mean titers of patients with the TT genotype were 44.5,
for TG 56.6, and for GG 80.0. The median fold changes from pre-
to post-vaccine were 2-fold in TT genotypes, 2-fold in TG and 4-
fold in GG. For Influenza B, the post-vaccine geometric mean
titers of patients with the TT genotype were 31.9, for TG 43.1,
and for GG 60.5. The median fold changes pre- to post-vaccine
were 1-fold in TT genotypes, 1-fold in TG and 1.5-fold in GG
(S1A–C Figure). The immunosuppressive drug dosages were not
significantly different between the genotypic groups (S1 Table).
This response was primarily driven by seroconversion to influenza
A/H1N1 and H3N2 (S3 Table).
The association between genotype and seroconversion was most
pronounced in patients receiving comparatively more potent
immunosuppressive therapy (i.e., those patients receiving $2 g
daily dose mycophenolate mofetil (MMF)). In this group, minor-
allele carriers for SNP rs8099917 showed markedly higher
seroconversion rates (OR 7, 95% CI 2.3–21.5; p,0.0001;
n = 80; Fig. 1C).
When analysing seroprotection to at least one antigen, both the
baseline and post-vaccination seroprotection rates were high
(71.2% for prevaccination and 88.2% post-vaccine seroprotection
to at least one antigen). No significant differences were seen
between genotypes likely due to the high rate of baseline
seroprotection to at least one antigen (Fig. 1D–F). To allow for
better interpretation of seroprotection date we analysed seropro-
tection to at least two vaccine antigens as an outcome. In this
analysis, the minor allele group (for rs8099917) had a trend
towards greater seroprotection (p = 0.062). In the subgroup of
patients receiving MMF$2 g daily, seroprotection to at least two
antigens was significantly greater in the minor allele carriers
(p = 0.038) (S1D–F Figure).
Author Summary
Infection with influenza viruses is associated with high
morbidity and mortality. Therefore, vaccination is recom-
mended in immunosuppressed patients, however often
the post-vaccine induced protection is insufficient. Factors
associated with reduced vaccine responses may guide
preventive strategies and could offer novel targets for
adjuvants. Here, we explore the impact of IL-28B on B- and
T-cell responses during vaccination. We found that a single
nucleotide polymorphism (minor allele genotype) in the IL-
28B gene was associated with a significant increase in the
antibody seroconversion rate following influenza vaccina-
tion. Interestingly, this SNP reduces the expression of IL-
28B. In addition, in vitro stimulation of peripheral blood
mononuclear cells from patients with the SNPs had
increased IL-4 production in CD4 T-cells. As a potential
mechanism, we show that recombinant IL-28B inhibits
influenza stimulated Th2 cytokine release, B-cell activation/
proliferation and H1N1-induced IgG secretion. Next, we
developed antagonistic peptides to block the IFN-l
receptor. Pre-treatment with the antagonistic peptides
increased in vitro B-cell activation and antibody production
in healthy individuals and transplant recipients. Together,
these findings identify IL-28B as a key regulator of Th1/Th2
balance during influenza vaccination. Blockade of the IFN-
l receptor with antagonistic peptides may offer a novel
strategy to augment vaccine responses.
IL28B and Vaccine Response
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No statistically significant difference in vaccine response was
evident for the SNP rs12979860 (S4 Table). Therefore, the
remaining experiments were performed focusing on the SNP
rs8099917.
Seroconversion in transplant recipients, the balance of
Th1/Th2 cytokine release and B-cell activation is
modulated by IL-28B. We next determined whether the IL-
28B SNP (rs8099917 TT versus TG/GG) exerted distinct effects
on T- and B-cell activation within the transplant patient cohort. In
a subset of vaccine recipients (n = 47), we obtained peripheral
blood mononuclear cells (PBMCs) both pre- and post-vaccination
and stimulated them with the same inactivated influenza A/H1N1
virus as contained in the vaccine. Of these, 16 (34%) seroconverted
using the HAI assay after vaccination. In the subgroup that
Figure 1. IL-28B genotype significantly impacts Influenza H1N1-stimulated immune responses in transplant recipients. (A) Percent
seroconversion to at least one influenza strain antigen in T/T (major) versus T/G or G/G (minor) IL-28B SNP in transplant recipients (rs8099917). Chi2
test was used to determine significance. (B) Percent seroconversion to at least one influenza strain antigen in T/T vs. T/G vs. G/G IL-28B SNP in
transplant recipients (rs8099917). (C) Percent seroconversion to at least one influenza strain antigen in T/T (major) versus T/G or G/G (minor) IL-28B
SNP in transplant recipients (rs8099917) receiving 2 g or more mycophenolate mofetil (MMF) per day. (D) Percent seroprotection to at least one
influenza strain antigen in T/T (major) versus T/G or G/G (minor) IL-28B SNP in transplant recipients (rs8099917). Chi2 test was used to determine
significance. (E) Percent seroprotection to at least one influenza strain antigen in T/T vs. T/G vs. G/G IL-28B SNP in transplant recipients (rs8099917). (F)
Percent seroprotection to at least one influenza strain antigen in T/T (major) versus T/G or G/G (minor) IL-28B SNP in transplant recipients (rs8099917)
receiving 2 g or more mycophenolate mofetil (MMF) per day. (G) Analysis of H1N1-stimulated Th1 cytokine release in transplant recipients with
seroconversion against H1N1 Influenza from post–vaccine samples stratified according to IL-28B minor or major-allele genotypes. The rs8099917 TT
(major allele, n = 7) compared to non-TT (minor allele, n = 7) genotypes are shown. Peripheral blood mononuclear cells (PBMCs) were stimulated
overnight with inactivated Influenza A/H1N1 (0.3 mg/mL hemagglutinin). The expression profile of 17 cytokines was determined using a luminex-
based platform. Key representative Th1 cytokines are shown. Mann Whitney U (MWU)-test determined statistically significant differences between
groups; bars show median values (C–F). For some individuals the cytokine values were below the limit of detection and thus were given values of the
lowest value in the linear range of the assay. (H) Frequency of post-vaccine H1N1-specific Interleukin (IL)-4 producing CD4+ T-cells in transplant
recipients with seroconversion according to IL-28B genotype (rs8099917, n = 7 each). For flow cytometry gating strategy see S4 Figure. In PBMCs with
a TT genotype 28.6% showed a .2-fold increase from unstimulated samples vs. H1N1 stimulated samples. In PBMCs with a no-TT genotype 85.7%
showed a .2-fold increase from unstimulated samples vs. H1N1 stimulated samples (p = 0.031). (I) HLA-DR surface expression (mean fluorescent
intensity (MFI)) on H1N1-stimulated naı¨ve B-cells (CD20+CD272) in transplant recipients stratified according to the IL-28B genotype (rs8099917) for
only those who seroconverted. PBMCs were stimulated with inactivated H1N1 influenza overnight. Baseline values represent non-antigen controls.
doi:10.1371/journal.ppat.1004556.g001
IL28B and Vaccine Response
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seroconverted, cytokine profiling of H1N1-stimulated PBMCs
post-vaccination showed that Th1-cytokines and associated
chemokines, such as IFN-a, interleukin (IL)-2, IL-6, and IFN-c
induced protein (IP)-10, were expressed at significantly lower levels
in minor-allele genotype patients (rs8099917, TG and GG;
Fig. 1G). S5 Table provides a comparison of post-vaccination
cytokine release dependent on genotype independent of serocon-
version. A heat map and principal component analysis (PCA)
including all samples indicated that pre- and post-vaccine samples
had significant differences in Th1/Th2 cytokine expression
according to the IL-28B genotypes (TT versus TG/GG). For
example IL-5 was relatively 2.9-fold higher expressed in minor-
allele carriers, whereas IL-2 was relatively 4.3-fold less expressed in
minor-allele carriers. The comparison of the cytokine expression
profiles related to seroconversion status and genotype demonstrate
that minor-allele carriers have a markedly lower Th1- compared
to a higher Th2-response. This shift is even further increased in
post-vaccine samples (S1G Figure). The differences in expression
dynamics of cytokines and clustering according to genotypes are
highlighted also in a two-dimensional PCA (S1H–I Figure). In
addition, minor-allele transplant patients (TG/GG) with H1N1-
seroconversion had significantly higher frequencies of H1N1-
stimulated IL-4-producing CD3+CD4+ T-cells compared to
major-allele genotype patients (TT) in post-vaccine samples
(p = 0.007, Fig. 1H). These data indicate that minor-allele carriers
have significantly lower H1N1-stimulated Th1- but higher Th2
cytokine release compared to major-allele carriers.
We also studied B-cell phenotypes in the context of the
rs8099917 IL-28B genotype because a major protective outcome
of influenza vaccination is activation of antibody producing B cells.
Most strikingly, minor-allele carriers with seroconversion had
significantly higher expression of H1N1-induced HLA-DR
expression compared to major-allele carriers (Fig. 1I, TG/GG
versus TT).
Recombinant IL-28B decreases influenza induced early
Th2 cytokine production, B cell proliferation and IgG
production. Since previous studies had indicated that minor
allele carries expressed lower levels of IL-28B [25,29–33], we
hypothesized that adding exogenous recombinant IL-28B to
PBMCs should mimic the major-allele phenotype (TT), i.e. increase
Th1- and decrease Th2-responses. First, we measured the in vitro
effect of IL-28B on early cytokine-production by H1N1-stimulated
PBMCs from transplant recipients using overnight stimulation
assays. In samples pre-treated with IL-28B, we observed a
significant increase in H1N1-stimulated Th1-cytokine expression
(IFN-c, IL6; Fig. 2A, S6 Table). In concordance with our previous
findings, pre-treatment of transplant recipients’ PBMCs with IL-
28B prior to H1N1-stimulation led to a .2-fold reduction in IL-4
production by CD3+CD4+ T-cells (Fig. 2B). Interestingly, the effect
was particularly pronounced in patients with a minor allele
genotype (TG or GG) (S2 Figure). Further, in transplant recipients,
we showed that recombinant IL-28B significantly decreased H1N1-
induced IgG production (p = 0.004) (Fig. 2C).
Healthy volunteer studies
SNP in IL-28B (rs8099917) is associated with lower mRNA
expression of IL-28B in H1N1 stimulated PBMCs from
healthy volunteers.. In addition to examination of the effect of
IL-28B in our transplant patient cohort, we also wanted to confirm
our findings in a non-immunosuppressed cohort and to explore
manipulation of the IL-28B system using healthy volunteer cells.
We therefore examined the association between the IL-28B
genotype (rs8099917) and H1N1-stimulated expression of IL-28B
in a cohort of healthy volunteers (HV, n = 28 TT-genotype, n = 21
non-TT genotype). We determined the relative expression of IL-
28A, IL-28B, and IL-29 mRNA in PBMCs stimulated with
influenza A/H1N1. rs8099917 minor-allele carriers had signifi-
cantly reduced mRNA-expression of IL-28B whereas IL-28A and
IL-29 were not affected (p = 0.0006; Fig. 3A). Plasmacytoid
dendritic cells (pDC) have recently been shown to be one of the
major producers of IL-28B [34–36]. The frequencies of pDCs
were comparable between major- and minor-allele groups in the
recruited HVs (major-allele carriers 0.39% vs. minor-allele carriers
0.45%; p = 0.713), suggesting that the changes in expression were
not due to frequency differences. Second and very important, in a
subset of PBMCs from healthy volunteers (n = 25), we pre-treated
immune cells with the immunosuppressive drug mycophenolate
mofetil (MMF). We found no difference in IFN-l expression
profiles at various concentrations of MMF (Fig. 3B). This suggests
that the impact of the genotype is an independent factor associated
with influenza-induced IFN-l gene expression.
IL-28B decreases late Th2 cytokines, B cell proliferation,
and IgG production in healthy volunteers. Since MMF may
influence Th-2 cytokines and B-cell responses, we measured the in
vitro effect of IL-28B on late cytokine-production by PBMCs from
HVs using a 5-day stimulation assay (n = 9). The 5-day stimulatory
assay allowed for the secretion of Th2 cytokines that are expressed
late during the stimulation. We observed a significant decrease in
the production of cytokines trophic for B-cells such as GRO,
Fractalkine, and Th2-cytokines (IL-4, IL-5, IL-9, and IL-13)
(Fig. 4A and S7 Table). An independently recruited cohort of HVs
confirmed the key findings of Th1 and Th1-associated cytokines
being significantly up-regulated (IFN-a, IL12p40, TNF- a, and IL-
6) at early time-points after stimulation. IFN-c showed a trend for
upregulation. In contrast, Th2 and Th2-associated cytokines were
down-regulated at later time-points (S3 Figure).
We then investigated the effects of IL-28B on H1N1-stimulated
B-cell proliferation and antibody production. IL-28B pre-treated
PBMCs from non-immunosuppressed HVs (n = 6) showed a dose-
dependent decrease of H1N1-stimulated B-cell proliferation. In
particular memory B-cells exhibited a 70% reduction in prolifer-
ation capacity (Fig. 4B). This impairment of proliferation was also
reflected in a 70% lower H1N1-stimulated IgG antibody
production at the highest dose of IL-28B added (Fig. 4C). We
also examined virus-specific antibody production against purified
H1N1 hemagglutinin and against the whole virions; these were
significantly decreased with a median 57% and 79% reduction at
the highest dose of IL-28B added, respectively (Fig. 4D). Taken
together, we demonstrate that IL-28B is a potent inhibitor of virus-
stimulated B-cell activation and antibody production independent
of immunosuppression. Based on live/dead staining, the inhibitory
effects were not due to toxicity (median % dead cells IL-28B 0 ng/
mL: 19.2%; 1 ng/mL: 19.9%; 10 ng/mL: 23.6%; 100 ng/mL:
22.6%; p = 0.92).
Antagonistic peptides to IL28RA promote greater
influenza induced antibody production. The above findings
are highly suggestive of IL-28B possessing a strong immunoreg-
ulatory influence on the balance between Th1 and Th2 immune
responses, which is in agreement with previous in vitro studies for
IL-29 [18–21,37,38]. In turn, this could considerably influence B-
cell functions in vivo. There are no published crystal structures for
IL-28B [39], thus we initially generated a model of the interaction
between IL-29 and the IL28-receptor alpha subunit (IL28RA),
and then designed peptides based on the known homologies
between the different IFN-ls [29]. Peptides with lengths of 14–
20 aa were generated to inhibit potential sites of interaction
between the ligand and receptor considering close proximity and
side-chain interactions (Fig. 5A–B, S5A–B Figure, and S8 Table).
IL28B and Vaccine Response
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Antagonistic peptides (10 mM) significantly reduced the binding
of IL-28B to IL28RA using a competition ELISA assay (S5C
Figure). Most of the scramble control peptides did not show a
specific antagonistic effect (S5D Figure), however for some
unspecific blocking effect could be observed, likely due to the
charged nature of the peptide. Of note, the scrambled versions
always showed a much lower inhibitory potential compared to the
antagonistic peptides.
Antagonistic peptide 1 reduced the binding of IL-28B to
IL28RA by 71%, but the scramble version did not block binding
at all. Therefore, we explored the blocking capacity of peptide 1 in
more detail using an ELISA competition assay with increasing
concentrations of antagonistic and scramble peptide control
compared to a consistent concentration of IL-28B. We observed
a potent specific dose dependent inhibitory blocking effect
(Fig. 5C).
Figure 2. Recombinant IL-28B inhibits Influenza H1N1-induced Th2 response and B cell activation in transplant recipients. (A)
Analysis of H1N1-stimulated Th1 cytokine release in transplant recipients (n = 36) from post–vaccine samples in relation to IL-28B pre-treatment.
Peripheral blood mononuclear cells (PBMCs) were pre-treated with recombinant IL-28B (100 ng/mL) for two hours prior to overnight stimulation with
inactivated Influenza A H1N1 (0.3 mg/mL hemagglutinin). The expression profile of 17 cytokines was determined using a luminex-based platform. Key
representative Th1 cytokines are shown. Wilcoxon matched-pairs signed rank (WCR)-test determined statistically significant differences between
groups. Before-after plots are shown where each dot is a different patient. (B) PBMCs from transplant recipients were pre-treated with recombinant
IL-28B (100 ng/mL) for two hours prior to overnight stimulation. Frequencies of H1N1-specific IL-4-producing CD4+ T-cells were measured by
intracellular flow cytometry as described in Methods. Data from 47 transplant recipients are shown in PBMC collected pre- and post-vaccine. (C)
PBMCs from transplant (Tx) recipients were pre-treated with recombinant IL-28B (100 ng/mL) for two hours prior to 5-day stimulation with H1N1. The
production of H1N1-induced IgG is shown according to pre-treatment groups. Data from 38 transplant recipients are shown.
doi:10.1371/journal.ppat.1004556.g002
IL28B and Vaccine Response
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The successful interaction between IL28RA, IL10RB and an
IFN-l ligand leads to an immediate phosphorylation of STAT1
and STAT2. Therefore, we used a functional assay based on
THP1-derived macrophages to screen the impact of IL28RA
blockade on STAT1 phosphorylation. Due to the higher IL28RA
expression, THP1-derived macrophages served as an ideal
screening model for our designed antagonistic peptides. In our
flow cytometry assay, STAT1 phosphorylation peaked in THP1-
derived macrophages 15 minutes after IFN-l and IFN-a stimu-
lation (S5E Figure). We examined the phosphorylation of STAT-1
induced by IL-28B in the presence and absence of the antagonistic
peptide ‘‘peptide 1’’. Treatment with blocking peptide 1 showed a
significant reduction in STAT1-phosphorylation upon challenge
with IL-28B compared to a scramble peptide control (Fig. 5D). A
dose dependent effect of antagonistic peptide 1 on IL-28B-induced
STAT phosphorylation could be shown with increasing concen-
trations (Fig. 5E) in a range similar to that of the ELISA
competition assay. This indicates that the peptide not only off-
competes the binding to the IL28RA, but also reduces the
functional interaction and down-stream signalling of the whole
IL28RA/IL10RB/IFN ligand complex.
In vitro effect of Peptides. We next examined the potential
of the peptides to reverse the inhibitory effects of IL-28B signalling
on H1N1-stimulated B-cells. We screened all the peptides for their
ability to enhance antibody production. PBMCs from HVs pre-
treated with an antagonistic cocktail of peptides 6, 16 and 17
showed a significant increase in H1N1-induced IgG production
after a five-day stimulation compared to peptide controls (Fig. 5F).
Peptides 1, 15 and 18 also showed a strong trend for higher H1N1-
induced IgG secretion. Next, we wanted to explore if the effects
observed were specifically enhancing H1N1 stimulated IgG
production. We tested a broad array of eight different control
peptides for their potential to induce changes in the IgG secretion
in an expansion protocol. We added fresh peptides twice during
the expansion protocol to maximize a potential effect. For various
individual IL28RA antagonistic peptides and peptide combina-
tions, the fold change in IgG production was greater than for their
respective control peptides. Figure S6 provides results on
additional non-functional peptide controls (S6 Figure). This clearly
indicates that the increase of H1N1 stimulated IgG production
due to the antagonistic peptides is relevant.
Next, we used PBMCs from transplant recipients who had not
seroconverted against H1N1-influenza. A combination of peptides
6, 16, and 17 prior to H1N1-stimulation increased the expression
of the H1N1-stimulated B-cell activation markers CD86, HLA-
DR and CD69 (Fig. 5G) and significantly increased H1N1-
stimulated IgG production by 38% compared to peptide controls
(median no peptides 226 pg/mL vs peptides 313 pg/mL;
Fig. 5H).
Discussion
We have determined in an immunocompromised transplant
population that the presence of the rs8099917 single nucleotide
polymorphism (SNP; TG or GG) in the IL-28B gene significantly
increases the likelihood of seroconversion to an influenza vaccine
especially in those people on high doses of immunosuppression.
We also showed that IL-28B affects Th2 and B-cell responses in
the context of influenza stimulation. Other important factors
associated with B-cell functions such as T-follicular helper cells
and IL-21 [40] were not studied.
IL-28B (IFN-l3) belongs to the family of IFN-lambdas and
shares antiviral properties similar to IFN-a via induction of
interferon stimulated genes (ISGs) such as MX1 or OAS1 [41]. In
addition, IL-28B has been shown to induce IL-12 production in
monocytes and macrophages. IL-12 is a key cytokine for the
induction of Th1 cells and cytotoxic lymphocytes [42,43]. SNPs in
the IL-28B gene (minor-allele genotypes) have been associated
with reduced IL-28B expression [25,29–33], which could impact
adaptive immune functions during vaccination. One limitation of
our study is that we did not measure serum levels of IL-28B. To
the best of our knowledge, no reliable ELISA assay is currently
available, which can differentiate between the high sequence
homology of IL-28A and IL-28B [44]. In addition, since our study
Figure 3. The minor-allele IL-28B genotype is associated with significantly lower expression of IL-28B, but not IL-29 or IL-28AmRNA
in healthy volunteers. (A) PBMCs from healthy volunteers were stimulated for six-hours with H1N1. mRNA-expression of IL-28A, IL-28B and IL-29
were normalized to non-stimulated controls and HPRT expression. Major (rs8099917 TT, n = 28) compared to minor (rs8099917 non-TT, n = 21) allele
genotype. MWU-test determined statistically significant differences between groups. Bars show median values with interquartile range. (B) PBMCs
from healthy volunteers (n = 25) were pre-treated with mycophenolate mofetil for 2 h prior to stimulated for six-hours with H1N1. mRNA-expression
of IL-28A, IL-28B and IL-29 and statistical analysis were performed using the Kruskal Wallis (KW) test.
doi:10.1371/journal.ppat.1004556.g003
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only evaluates patients 30 days post-vaccination, we may not
capture the peak of IL-28B secretion. Approximately 40% of
Caucasians and 10% of Asian populations carry IL-28B minor-
allele genotypes [27]. SNPs in IL-28B have been best studied in
the context of response to Hepatitis C therapy. Minor-allele
genotypes in IFN-l signalling have been associated with reduced
sustained virologic response of hepatitis C virus (HCV) following
IFN-a treatment [24–27]. In contrast patients with a IL-28B
minor-allele genotype and also at high-risk for primary infection
with Cytomegalovirus, had lower frequencies and shorter episodes
of primary CMV replication [29,45]. Patients with minor-allele
genotypes of IL-28B showed lower expression of IFN-l during
HCV infection in liver biopsies [25,30] and during stimulation of
PBMCs with CMV [29].
Previous studies have shown that vaccine responses may be
influenced by SNPs in interleukin genes. For example, hepatitis B
vaccine responses may be influenced by SNPs in the IL-4 gene
[46]. SNPs in interleukin genes may also affect humoral and
cellular responses to the measles vaccine [47]. In a large cohort of
children vaccinated against measles, the rs10853727 SNP in the
IL-28B promoter was strongly associated with post-vaccine titers.
The major-allele genotype (AA) showed significantly lower measles
antibody titers compared to the minor-allele genotypes (AG and
GG; median 807 vs. 1004, and 1727 mIU/mL, respectively;
p = 0.021) [47].
The effects of SNPs on vaccine responses in the general
population may be demonstrated through large-scale genome-
wide association studies. However, an immunosuppressed cohort
with poor adaptive immunity can be ideal to demonstrate
immunogenetic differences in vaccine responses.
We found that the association of the IL-28B SNP with influenza
vaccine seroconversion and seroprotection (to at least two vaccine
antigens) was even more significant in transplant patients on high
doses of mycophenolate mofetil (MMF). MMF is well known to
significantly suppress influenza vaccine responses [28,48] by
having an effect on virus-specific Th2 cytokines [49] and on B-
Figure 4. Recombinant IL-28B inhibits Influenza H1N1-induced Th2 response and B cell activation and IgG production in healthy
volunteers. (A–D) PBMCs from healthy volunteers were pre-treated with 1 ng/mL, 10 ng/mL, or 100 ng/mL rIL-28B for two hours prior to 5-day (A–
C) or 7-day (D) stimulation with H1N1. Kruskal Wallis-test was used to determine statistically significant differences. (A) Cytokine profile after
stimulation with H1N1 according to pre-treatment groups (n = 9). (B) B-cell proliferation was quantified using Cell Trace Violet proliferation dye
staining. CD20 and CD27 served as cell-type and memory markers, respectively (n = 6). (C) Total amount of IgG in supernatants in an independent
cohort of HVs was determined using by ELISA (n = 8). (D) The amount of H1N1- and HA-H1N1-specific IgG in supernatant was determined by ELISA
(n = 9, and n = 8 (1 donor did not produce HA-specific IgG) respectively). The reduction of pre-to-post-treated PBMCs was calculated.
doi:10.1371/journal.ppat.1004556.g004
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Figure 5. Design of antagonistic peptides against IL-28 receptor alpha subunit (IL28RA) and their effects on H1N1-stimulated B-cell
functions. (A) Design of inhibitory peptides based on the crystal structures of IL-29 and the IL28RA. A computer prediction of the interaction
between IL-29 and the IL28RA is illustrated. Colored fragments represent proposed sites of significant interaction using a proximity model. (B)
Example for detailed in silico interaction between peptide 6 and IL-28Ra (peptides 9 and 11). (C) Inhibitory activity of antagonistic peptide 1 against
IL-28B binding to IL28RA. ELISA was used to measure the binding of a fixed concentration of IL-28B (100 ng/mL) to IL28RA challenged by increasing
concentrations of the inhibitory peptide and control peptide (scrambled version). The data shown is representative of three independently repeated
experiments. Whiskers indicate the interquartile range. (D) STAT1 phosphorylation in THP1-derived macrophages treated with peptide 1 and
challenged with recombinant IL-28B (100 ng/mL) for 15 min in comparison to scramble peptide control. Data of five individual experiments is shown.
Wilcoxon matched-pairs signed rank (WCR)-test was used. (E) STAT1 phosphorylation in THP1-derived macrophages treated with different doses of
peptide 1 and challenged with recombinant IL-28B (100 ng/mL) for 15 min in comparison to scramble peptide 1 control. Symbols represent median
of three independently repeated experiments. (F) PBMCs from healthy volunteers were pre-treated with peptides for two hours prior to 5-day
stimulation with H1N1. In addition recombinant IL-28B (28B) and control peptides (c1, SV40-based peptide; c2, a duck hepatitis B virus based peptide,
and various scrambled versions of the peptides) were used. Total IgG in supernatant was determined using an ELISA and fold changes are shown
calculated over peptide treatment alone (no H1N1). MWU-test determined statistically significant differences between groups, p,0.05(*). Bars show
median and inter-quartile ranges; whiskers indicate 10–90th percentile. (G–H) PBMCs from transplant recipients without successful seroconversion
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cell activation markers, and seroconversion rates [28]. The minor-
allele genotype in patients treated with more than two grams
MMF per day demonstrated significantly higher seroconversion
rates – essentially acting similar to a ‘‘rescue’’ mutation. We
speculate that major-allele carrier status with high IL-28B
expression in addition to receiving high-dose MMF therapy leads
to a ‘‘double hit phenomenon’’ on Th2 responses. As a limitation
of our work, we recruited healthy volunteers over multiple months,
therefore the numbers within various experiments are variable and
some intra-individual variation may be present.
We also determined that the IL-28B rs8099917 SNP affected
not only humoral responses to the influenza vaccine but also had a
potent effect on cellular responses by modulating the Th1/Th2
cytokine balance. We show that the IL-28B minor-allele genotype
is characterized by a predominant Th2-response upon stimulation
with H1N1-influenza virus, and is associated with increased B-cell
activation (HLA-DR, CD86) and function (IgG production).
Although we did not measure H1N1-specific IgG in transplant
patients, we do show in healthy volunteers that virus-specific IgG
decreases upon pre-treatment with IL-28B in vitro at similar
inhibition levels. Furthermore, exogenous treatment with IL-28B
simulated a major-allele phenotype with significantly reduced Th2
cytokine expression. In PBMCs from healthy volunteers, this
phenomenon was independent of MMF treatment. Our findings
confirm the previous observation that IL-29 may skew the balance
of Th1 and Th2 cytokine towards Th1 and a pronounced
cytotoxic T-cell response [18,19,21,38]. Secretion of Th1-
cytokines acts as an important suppressor of Th2-cell differenti-
ation [50,51] via IFN response factors [51] and is associated with
lower antibody titers after influenza vaccination [52]. Interestingly,
the effect of IL-28B treatment was stronger in minor allele
genotypes. The reduced effects in major allele genotypes could be
due to a higher baseline expression of IL-28B and saturation of the
signalling cascade. This is supported by a study in hepatocytes,
where the minor allele genotype was associated with a higher
baseline IL28RA expression and increased susceptibility and
responses to IFN-ls [53]. A similar mechanism could be present in
antigen presenting cells, which in turn has then affects the down-
stream effects on T-cells and antibody production.
We further used peptides to inhibit IL-28R signalling. These
peptides have previously been described [29]. Inhibition of the IL-
28B signalling during vaccination offers the potential to enhance
Th2 cytokine release and thereby boost pathogen-specific IgG. It
has been previously shown that signalling of the IFN pathway
suppresses IgG secretion via increasing Th1 cytokines and a more
cytotoxic immune response [52]. In particular antagonistic
peptides 1, 6, 16 and 17 are promising candidates with high
binding affinities to IL28RA, a strong potential to inhibit binding
of IFN-ls and the ability to significantly increase in vitro H1N1-
induced IgG production. These antagonistic peptides may enable
immunomodulation towards Th2 cytokines and have the potential
to become a new class of adjuvants by modulating IFN.
An important strength of our study is the use of a clinical cohort
including immunosuppressed transplant recipients to confirm our
findings in the clinical setting. We then sought to define additional
observations to support our clinical findings making our study
unique. One limitation of our study is the heterogeneity of the
transplant cohort due to a variety of underlying conditions leading
to organ failure. However, the immunosuppressive treatment was
not significantly different between genotype groups. In addition,
we have shown that mycophenolate mofetil (MMF) and the IL-
28B major-allele genotype are independent factors for IgG
production and that IFN-l mRNA expression is not influenced
by MMF. Another limitation of our study was that at the time of
peptide design, only the crystal structure of IL-29 was available
and the peptides are therefore based on IL-29 and not IL-28B.
However, as IL-29 has a significantly greater binding affinity
towards IL28RA compared to IL-28B, this could be advantageous
as we are potentially blocking all IFN-ls with greater efficiency.
The role of the IL10RB co-recruitment also needs to be further
defined.
In summary, SNPs in IL-28B play a key role in vaccine
responses especially for influenza vaccine response in immuno-
suppressed patients. Peptides used to inhibit IFN lambda receptor
signalling may play a role in augmenting vaccine responses and as
such, represents a novel avenue for developing new adjuvants.
Further studies in other populations such as other immunosup-
pressed populations, elderly persons and healthy individuals would
also lead to improved vaccine strategies.
Materials and Methods
Patient population
A previously described cohort of immunosuppressed adult solid
organ transplant recipients was used for this study [28]. Healthy
non-immunosuppressed non-vaccinated volunteers (HV) were
recruited as controls. Peripheral blood mononuclear cells (PBMCs)
from 47 transplant recipients were available.
Ethics statement
The study protocols were approved through the University of
Alberta research ethics board and written informed consent was
obtained from all participants (patients and healthy volunteers).
Hemagglutination inhibition assay
HAI titers were determined as previously published [28].
Definitions of vaccine responses
Definitions of vaccine immunogenicity were based on recom-
mendations for annual licensure of influenza vaccine (European
Medicines Agency, document: CHMP/VWP/164653/2005).
Seroconversion was defined as a $4-fold rise in titer from pre-
vaccination. Vaccine response was defined as seroconversion to at
least one of the three vaccine antigens: influenza A/California/7/
2009(H1N1-like), A/Victoria/210/2009(H3N2-like) and B/Bris-
bane/60/2008 [28].
Genotyping of polymorphisms in the IL-28B promoter
region
SNP genotypes were determined as previously published
[29,54,55]. Briefly, the probe set to discriminate the rs12979860
discriminates the C and T alleles, where C is the major, and T is
the minor-allele [55]. For the rs8099917 SNP, the probe set
discriminates the T and G alleles, where T predicts the major, and
G is the minor-allele. SNP detection was performed on 6 ng of
genomic DNA. S9 Table shows all primer sequences. In each
allelic discrimination assay 50 bp synthetic positive control
were pre-treated with the IL-28Ra antagonistic peptides (6, 16 and 17) prior to overnight stimulation with H1N1. The mean fluorescence intensity
(MFI) of CD86, HLA-DR, and CD69 on B-cells (CD20+) was measured using flow cytometry (G). The amount of H1N1-stimulated IgG release was
determined by ELISA (H). Wilcoxon matched-pairs signed rank (WCR)-test determined statistically significant differences between groups.
doi:10.1371/journal.ppat.1004556.g005
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oligonucleotides were included. SNP genotype was determined
using the automatic call algorithm in conjunction with the allelic
discrimination plot.
Influenza viruses
For immune stimulation we used formalin inactivated, partially
purified A/California/7/2009 (H1N1) (NIBSC, NXMC-X179A,
UK). The H1N1 stock contained 50 mg/mL of hemagglutinin
protein and was re-constituted in water. For all experiments a final
concentration of 0.3 mg/mL was used.
IL-28A, IL-28B and IL-29 specific TaqMAN gene
expression assay
IL-28B primers and probe were designed based on Homo sapiens
IL-28B mRNA-sequence (NM_172139.2) using Primer3 Input
(version 0.4.0) (http://frodo.wi.mit.edu/). The forward primer (IL-
28BF1: CAAAGATGCCTTAGAAGAGTCG) spans the exon/
exon junction of exons 1 and 2 of IL-28B. The IL-28B-specific
probe (IL-28B probe: GCTGAAGGACTGCAAGTGCCG) is
located in the second exon and the reverse primer (IL-28BR1:
TCCAGAACCTTCAGCGTCAG) is in the third exon of the IL-
28B gene. For IL-28A, the Homo sapiens IL-28A mRNA-sequence
(NM_172138.1) was utilized. The forward primer (IL-28AF1:
CAAAGATGCCTTAGAAGAGTCG) spans the exon/exon junc-
tion of exons 2 and 3 of IL-28A. The IL-28A-specific probe (IL-28A
probe: GCTGAAGGACTGCAGGTGCCA) is in exon 3 and the
reverse primer (IL-28AR1: TCCAGAACCTTCAGCGTCAG) is
found in the fourth exon. Forward and reverse primers were
identical for both genes due to high percentage sequence homology.
Assay specificity was conferred by a two-nucleotide difference in the
probe sequence (underlined). Both assays yield 150 nt products.
Primers and a probe specific for IL-29 were designed based on
the Homo sapiens IL-29 mRNA-sequence (NM_172140.1). The
forward primer (IL-29F1: GGACGCCTTGGAAGAGTCA) spans
the exon/exon junction of exons 1 and 2 of IL-29. The IL-29-
specific probe (IL-29 probe: CTCAAGCTGAAAAACTGGAGT-
TGCAGC) is in the second exon of the IL-29 gene and the IL-29
reverse primer (IL-29R1: CCAGGACCTTCAGCGTCA) is in the
third exon. The IL-29 assay yields a product of 146 nucleotides.
Primers and probes were manufactured by IDT (Integrated DNA
technologies, Iowa, USA).
The specificity of the three sets of qRT PCR assays was tested
against Invivogen expression plasmids containing complete IL-
28A (puno1-hIL-28A), IL-28B (puno1-hIL-28B) and IL-29
(punoIL-29) sequences [16]. The specificity of all qRT PCR
assays has been previously assessed [29]. As a house keeping gene
HPRT was used [29].
IgG ELISA for influenza-induced antibodies
Cell-free supernatants were collected from PBMC cultures at
indicated time points and stored at280uC until analysis. An in-house
human IgG ELISA assay was developed using antibodies and human
IgG standard. In brief, 96 well EIA/RIA plates (Costar) were coated
overnight with donkey anti-human IgG antibody at 5 mg/ml. Plates
were washed with PBS/0.05% Tween and supernatant samples
(diluted 1:5) or ChromPure Human IgG standard (Jackson Im-
munoresearch) were added in duplicate for 2 hrs at room temper-
ature. After washing extensively, detection antibody (goat anti-human
IgG alkaline phosphatase, 1:15,000) was added for 1 hr at room
temperature. After washing, PNPP substrate was added and the plate
was read every 5 min at 405 nm with correction at 570 nm.
Virus-specific IgG production was assessed by coating the
previously mentioned plates either with pH1N1 antigen (contained
in the vaccine, and used also for T-cell stimulation assays: NIBSC,
NXMC-X179A) or purified pH1N1 hemagglutinin (Influenza
reagent resource (IRR), FR-559). Supernatants from stimulated
PBMC cultures (day 7; diluted 1:2) were added and the amount of
bound antibody was determined as above except supernatants
were incubated overnight to increase sensitivity. To confirm
specificity, supernatants were added to plates coated with hepatitis
B virus surface antigen (Creative Biomart) or HCV E2 antigen
(Immunodiagnostics, Inc.) and no signal was detected above
background (Median ODs for HA coated wells: 0.607; HBs Ag:
0.00625; HCV E2: 0.00425; and unstimulated sample supernatant
with HA coated wells: 0.01175). Results are expressed as
absorbance values (405 nm–570 nm) with the plate blank
subtracted.
Design of peptides
Antagonistic peptides were designed as previously published
[29]. Briefly, based on previous publications of the crystal
structures of IL-29 and the receptor IL28RA (PDB: 3OG4,
3OG6), we determined the amino acid residues, which are in close
proximity to mediate interaction between the two molecules. The
selected amino acids were compared with the crucial amino acids
described in the literature [39,56]. In order to preserve the
interaction domain structure (helix or loop) we selected nearby
amino acids that may stabilize the binding domain for inclusion in
peptides.
Based on the oligomeric state structure suggested, we designed
peptides, which have the potential to bind both IFN-l and
IL28RA. We used the crystal structure of IL-28B oligomer (PDB:
3HHC [56]) focusing on amino acids, whose residues may be
involved in the interactions responsible for the formation of the
oligomeric state. We then designed peptides to mimic these
interaction domains in order to prevent the formation of
oligomers. All peptides (and all other reagents) were tested for
endotoxin and had ,0.25 endotoxin units (EU)/ml.
ELISA for competition assay
Recombinant IL28RA was coated on an ELISA plate and pre-
treated with increasing concentrations of peptides. Next, recom-
binant, his-tagged IL-28B at a fixed concentration of 100 ng/mL
was added. Anti-his secondary antibody was used to determine the
relative amount of bound IFN-l to the IL28RA. These dose-
response curves allowed us to determine the effectiveness of
binding inhibition of each peptide. Antagonistic peptides were
added in a range from 10 nM to 100 mM.
THP1-derived macrophages
THP1-derived macrophages were generated as previously
described [57]. Briefly, THP1 cells were seeded in presence of
PMA (100 nM) and incubated at standard conditions in RPMI
10% heat inactivated FCS for 3 days. Then media and non-
adherent cells were removed and fresh media without PMA added
for another 5 days incubation. These cells (THP1-derived
macrophages) where used for the peptide screening assays.
Flow cytometry
Prior to surface staining, LIVE/DEAD staining was performed
(near-IR; Invitrogen). Markers for identifying T-cell subsets were
CD3, and CD4. Intracellular cytokine staining was performed
according to previously published protocols after overnight
stimulation [58]. IL-4 was used as a key representative for Th2
cytokine production. Background (unstimulated samples) were
subtracted from stimulated results. All reagents including perm
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and fixation buffers and antibodies were from eBioscience. Isotype
controls have previously been used to establish the assays.
Markers for identification of B-cell subsets were CD20 and
CD27, where naı¨ve B-cells are CD20+CD272 and memory B-cells
are CD20+CD27+. MHC-II, CD86 and CD69 served as activation
markers (Biolegend or eBioscience; see S4 Figure). For B-cell
expansion experiments, PBMCs were labeled with Cell Trace
Violet proliferation dye (Invitrogen). Labeled PBMCs were
washed and resuspended in RPMI with 10% FBS and plated in
a 96-well format. Stimulation was according to the respective
experimental condition in 5% CO2 at 37uC. 2 days after initial
stimulation, 50 mL of fresh RPMI was added.
THP1-derived macrophages were stained using STAT1-phos-
phorylation antibodies (BD Bioscience, AF647 Mouse anti-stat-1
pY701) and respective isotype controls. Macrophages were
pretreated with blocking peptides and challenged with IL-28B
(100 ng/mL) for 15 min. Then cells were fixed and permeabilized
as previously described.
Cytokine profile
Two luminex-based cytokine profiling kits were used (Eve
Technologies, Calgary, Canada). (i) 17-plex: Fractalkine, IFN-a,
IFN-c, GRO, MCP-3, IL-13, sCD40-L, IL-9, IL-1b, IL-2, IL-4,
IL-5, IL-6, IP-10, MCP-1, MIP-1a, and TNF-a. (ii) 41-plex: EGF,
Eotaxin, FGF-2, FLT3, Fractalkine, G-CSF, GM-CSF, GRO.
IFN-a2, IFN-c, IL-1a, IL-1b, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17,
IP-10, MCP-1, MCP-3, MDC, MIP-1a, MIP-1b, PDGF AA,
PDGF AB/BB, RANTES, sCD40L, sIL2ra, TGF-a, TNF-a,
TNF-b, and VEGF. Our independent experiment for examining a
time course of cytokine induction was a custom-plex based on the
17-plex and still run and analyzed by Eve Technologies.
Cytokine profile analysis
GeneSpring GX version 12 (Agilent Technologies, Canada)
was used for cluster and principal component analysis (PCA) of
the cytokine data measured in H1N1-stimulated PBMCs. Non-
stimulated background samples were subtracted prior. Percentile
shift was used as normalization algorithm and baseline transfor-
mation was performed to median of all samples. Hierarchical
clustering of both conditions and cytokines was done using
Euclidean as similarity measure and Centroid as linkage rule.
PCA was used to detect major trends in the experimental
conditions. 2D PCA Scores are shown for the first and second
PCA components. They capture about 90% of the variation and
visualize the separation of the conditions. The PCA loading plot
indicates the separation in subsets of cytokines (x-axis) and
denotes their relative contribution to the principal components on
the y-axis. All pre- and post-vaccination samples of 47 transplant
recipients were included. The conditions considered for analysis
were: pre- vs. post-vaccination and minor- vs. major-allele IL-28B
genotype.
Statistical analysis
Statistical analyses were performed using PASW Statistics
(version 20.0, Chicago, Ill.) and GraphPad Prism (version 4.0,
La Jolla, CA). Data are shown with median and inter-quartile
ranges unless otherwise indicated. Categorical variables were
analyzed using a Chi-Square (Chi2). Continuous non-normal
distributed data (Shapiro Wilk test) were analyzed using a Mann-
Whitney U test (MWU) or Kruskal-Wallis test (KW). Paired data
were analyzed using Wilcoxon matched pairs rank test (WCR). All
tests were two-tailed.
Supporting Information
S1 Figure Analysis of H1N1-stimulated antibody and
cytokine release in transplant recipients. (A–C) Pre- to
post-vaccine haemagglutination inhibition (HAI) titer according to
genotype. The HAI titers are shown for major allele carriers (TT,
left) and minor allele carriers (no TT, right) for pH1N1 (A), H3N2
(B), and Influenza B (C). A total of 196 transplant recipients is
shown. (D–F) Seroprotection to at least two vaccine antigens. (D)
Percent seroprotection to at least two influenza strain antigens in
T/T (major) versus T/G or G/G (minor) IL-28B SNP in
transplant recipients (rs8099917). Chi2 test was used to determine
significance. (E) Percent seroprotection to at least two influenza
strain antigens in T/T vs. T/G vs. G/G IL-28B SNP in transplant
recipients (rs8099917). (F) Percent seroprotection to at least two
influenza strain antigens in T/T (major) versus T/G or G/G
(minor) IL-28B SNP in transplant recipients (rs8099917) receiving
2 g or more mycophenolate mofetil (MMF) per day. (G–I)
Supernatants of H1N1 stimulated PBMCs from transplant
recipients (n = 47) was collected after 18 h. A luminex-based
cytokine profile analysing 17 cytokines was performed. (G)
Clustering analysis comparing IL-28B genotype pre- and post-
vaccine (vacc.). (H) Principal component analysis showing PCA
scores dependent on IL-28B genotype and pre- vs. post-vaccine
state (2-dimensional). (I) Principal component analysis showing
PCA loadings of cytokines dependent on IL-28B genotype and
pre- vs. post-vaccine state (2-dimensional).
(TIFF)
S2 Figure Frequency of IL-4-producing CD4 T-cells and
impact of pre-treatment with IL-28B. The differential effect
of IL-28B genotype background in PBMCs before and after
vaccination is shown. In particular, PBMCs with a minor allele
background (no TT) show a strong sensitivity to IL-28B. Wilcoxon
matched pairs rank test was used to test for significant difference.
Data from 45 transplant recipients is shown.
(TIFF)
S3 Figure A cytokine profile with pH1N1 stimulation +/
2 IL-28B pre-treatment (100 ng/ml) was performed.
The time-points were collected within the same experiments. For
the first 3 HVs studied, d+5 sample was not collected. Overall, the
time-points d+1, d+3, d+7 were available in total 10 HVs and for
d+5 in 7 HVs. Wilcoxon matched pairs rank test was used to test
for significant difference.
(TIFF)
S4 Figure Gating strategy for flow cytometry analysis of
H1N1-specific T-cell and B-cell responses. (A) After
exclusion of singlets and dead cells, either T-cells (CD3+CD4+),
or B-cells (CD20+CD272, naı¨ve B-cells; CD20+CD27+, memory
B-cells; CD20+CD27++, plasma cells/plasmablasts) were gated. In
T-cells, intracellular cytokine staining for IL-4+ was determined.
Cytokine producing T-cell subsets were expressed as the %
frequency of overall CD3+CD4+ T-cells. In B-cells, surface
staining with CD86, HLA-DR and CD69 was determined. Mean
fluorescence intensity was used to express the surface expression of
the respective activation marker. Background expression (non-
stimulated cells) was subtracted for all experiments. (B) Examples
of IL-4 producing H1N1-stimulated and non-stimulated CD4+ T-
cells are shown. For further analysis the non-stimulated back-
ground sample was subtracted.
(TIFF)
S5 Figure Design of antagonistic peptides to IL-28
receptor (IL28RA) and their binding affinity. (A) Exampled
of detailed in silico interaction focusing on peptide 3 and IL28RA.
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(B) Exampled of detailed in silico interaction focusing on peptide 1
and IL28RA. (C) Inhibitory activity of peptides against IL-28B to
IL28RA. ELISA was used to measure the binding of a fixed
concentration of IL-28B (100 ng/mL) to IL28RA challenged by a
fixed concentration of antagonistic peptides (10 mM). Bars indicate
median values, whiskers inter-quartile ranges. The graph repre-
sents three independently repeated experiments. (D) Inhibitory
activity of scrambled peptides against IL-28B to IL28RA. ELISA
was used to measure the binding of a fixed concentration of IL-
28B (100 ng/mL) to the IL28RA challenged by a fixed
concentration of control peptides (10 mM; s, scramble). The
median value representing three independently repeated experi-
ments is shown. Whiskers indicate the interquartile range. (E)
Time-course of STAT-1 phosphorylation in THP1-derived
macrophages peak at 15 min. STAT-phosphorylation is expressed
in mean fluorescent intensities of 5 independent experiments,
mean and SEM is shown.
(TIFF)
S6 Figure Effects of control peptides on H1N1 stimu-
lated IgG production. Various control peptides were added
twice to H1N1 stimulated PBMCs to maximize a potential
unspecific stimulatory effect during the expansion phase. No
unspecific effect could be observed. Control peptides are
abbreviated as ‘‘ctrl’’. Ctrl 1–3, ‘‘DV2’’, ‘‘DV8’’, ‘‘DV10’’ are
peptides based on the NS5A of HCV, Ctrl 4, ‘‘DHBV’’ is a
peptide based on the pre S region of duck hepatitis B virus
encoded proteins. Ctrl 5, ‘‘Pen’’ is penetratin from drosophila, and
Ctrl 6, ‘‘SV40’’ is based on the large T protein in simian virus 40.
All control peptides are unrelated to IL-28A, IL-28B, IL-29 or
IL28RA or IL10RB.
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